GSK and China-based Hansoh Pharma have inked an exclusive license agreement for a B7-H3 targeted antibody-drug conjugate (ADC), marking the second ADC deal for the partners this year.
Under the agreement, GSK will make an upfront payment of $185 million, with potential success-based milestones of up to $1.525 billion for the early-stage asset, HS-20093. Upon commercialization, GSK will pay tiered royalties on global net sales outside of the specified territories.
The deal grants GSK exclusive worldwide rights, excluding China’s mainland, Hong Kong, Macau, and Taiwan, for the clinical development and commercialization of HS-20093. The ADC, utilizing a clinically validated topoisomerase inhibitor payload, has demonstrated promising clinical activity in lung cancer and is undergoing phase 1 and 2 trials in China. GSK plans to initiate phase 1 trials for HS-20093 outside of China in 2024.
This is the second deal for GSK and Hansoh this year. In October, GSK partnered with Hansoh on a phase 1 B7-H4 targeted ADC aimed at gynecologic cancers. As part of the agreement, GSK paid $85 million to Hansoh, with the potential for up to $1.485 billion in success-based milestones tied to the ADC candidate.